Trade Mind Medicine (MindMed) Inc. Subordinate Voting Shares - MNMD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.46 |
| Open | 5.54 |
| 1-Year Change | -43.76% |
| Day's Range | 5.46 - 5.78 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 5.76 | 0.30 | 5.49% | 5.46 | 5.81 | 5.43 |
| Apr 16, 2025 | 5.46 | -0.04 | -0.73% | 5.50 | 5.59 | 5.32 |
| Apr 15, 2025 | 5.54 | 0.04 | 0.73% | 5.50 | 5.82 | 5.42 |
| Apr 14, 2025 | 5.50 | -0.03 | -0.54% | 5.53 | 5.76 | 5.36 |
| Apr 11, 2025 | 5.40 | 0.37 | 7.36% | 5.03 | 5.41 | 5.00 |
| Apr 10, 2025 | 5.10 | -0.34 | -6.25% | 5.44 | 5.44 | 4.94 |
| Apr 9, 2025 | 5.66 | 0.94 | 19.92% | 4.72 | 5.76 | 4.67 |
| Apr 8, 2025 | 4.88 | -0.70 | -12.54% | 5.58 | 5.64 | 4.75 |
| Apr 7, 2025 | 5.33 | 0.32 | 6.39% | 5.01 | 5.49 | 4.79 |
| Apr 4, 2025 | 5.24 | 0.05 | 0.96% | 5.19 | 5.52 | 4.90 |
| Apr 3, 2025 | 5.52 | -0.05 | -0.90% | 5.57 | 5.70 | 5.41 |
| Apr 2, 2025 | 5.91 | 0.63 | 11.93% | 5.28 | 6.04 | 5.28 |
| Apr 1, 2025 | 5.50 | -0.24 | -4.18% | 5.74 | 5.78 | 5.45 |
| Mar 31, 2025 | 5.81 | -0.17 | -2.84% | 5.98 | 6.04 | 5.63 |
| Mar 28, 2025 | 6.15 | -0.11 | -1.76% | 6.26 | 6.44 | 6.07 |
| Mar 27, 2025 | 6.40 | -0.09 | -1.39% | 6.49 | 6.54 | 6.25 |
| Mar 26, 2025 | 6.54 | -0.07 | -1.06% | 6.61 | 6.75 | 6.39 |
| Mar 25, 2025 | 6.77 | -0.11 | -1.60% | 6.88 | 6.88 | 6.63 |
| Mar 24, 2025 | 6.91 | 0.10 | 1.47% | 6.81 | 7.01 | 6.60 |
| Mar 21, 2025 | 6.69 | 0.22 | 3.40% | 6.47 | 6.81 | 6.45 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Mind Medicine (MindMed) Company profile
Mind Medicine (MindMed) Inc is a biopharmaceutical company that develops clinical-stage psychedelic medicines to treat brain health disorders. The New York-based firm specialises in psychiatry, addiction, pain management and neurology.
Founded in May 2019, MindMed has several drug candidates targeting serotonin, dopamine and acetylcholine systems. These products are based on psychedelic and empathogen substances. The company’s main drug candidate is MM-120, which is a proprietary, pharmaceutically optimised form of LSD. The medication is being developed to treat generalised anxiety disorder (GAD). MindMed is also researching the drug in various dosing regimens for the treatment of attention deficit hyperactivity disorder, also known as attention-deficit/hyperactivity disorder (ADHD), as well as chronic pain.
MM-110, the company’s second advanced drug, is being developed to treat opioid withdrawal. The MM-110, also known by the non-proprietary name zolunicant, is a form of 18-methoxycoronaridine, an ibogaine congener.
The company’s third medicine candidate is MM-402, or R(-)-MDMA, a proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). The medicine is being developed for the treatment of core symptoms of autism spectrum disorder.
In addition to its advanced stage drugs, the company also has several earlier stage research programmes through external collaboration, including a multi-year exclusive partnership with University Hospital Basel (UHB) in Switzerland.
MindMed does not own or operate any manufacturing facilities. All clinical and non-clinical materials are supplied by third-party contract manufacturing organisations, or CMOs.
MindMed went public on 27 February 2020 on the Toronto-based NEO Exchange under the ticker ‘MMED’. It is listed on Nasdaq under the symbol ‘MNMD’ and in Germany under the ticker ‘BGHM’.
| Industry: | Biotechnology & Medical Research (NEC) |
One World Trade Center
Suite 8500
NEW YORK
NEW YORK 10007
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com